Industry Satellite Symposia

The sessions below took place during the 2023 Multidisciplinary Thoracic Cancers Symposium in New Orleans

The American Society for Radiation Oncology (ASTRO) has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposium. The symposia constitute the content and views of the provider and are not part of the official ASTRO Annual Meeting program.

Thursday, November 30, 2023

6:15 a.m. - 7:45 a.m.: Symposium

Roadmap to Success with Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care

Check out this online educational activity that provides comprehensive guidance on the evidence-based integration and practical use of current and emerging immunotherapy options as well as leveraging multidisciplinary and interprofessional collaboration in the context of new requirements and changing best practices to improve patient outcomes throughout the NSCLC disease continuum. Experts present illustrative case scenarios to frame in-depth reviews and interpretations of evidence supporting the use of immunotherapies in NSCLC to equip participants with the tools and strategies needed to improve patient outcomes.

Key Reasons to Attend

  • Keep up to date with current and emerging immunotherapy options and the evidence supporting their use across the NSCLC disease continuum.
  • Optimally integrate current and emerging immunotherapies into treatment plans for patients with metastatic, locally advanced unresectable, or early-stage resectable NSCLC to maximize beneficial outcomes for patients.
  • Develop strategies to more effectively communicate and collaborate with multidisciplinary team members to deliver exemplary patient-centered care.


Accreditation Statement
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation
CME: 1.5 AMA PRA Category 1 CreditsTM
MOC-ABIM: 1.5 MOC points and patient safety MOC credit
AAPA: 1.5 AAPA Category 1 CME credits
IPCE: 1.5 Interprofessional Continuing Education (IPCE) credits

This activity is supported by an independent educational grant from AstraZeneca.

Wednesday, November 29, 2023

Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC

Learning objectives:
  • Discuss the rationale for applying immunotherapeutic strategies to early-stage and locally advanced NSCLC settings, as well as key considerations in multidisciplinary care coordination among thoracic surgeons, medical oncologists, radiologists and radiation oncologists.
  • Design personalized care strategies to integrate evidence with evolving immunotherapy-based approaches to manage patients with resectable stage I-III NSCLC.
  • Analyze recent data and emerging trends utilizing immune checkpoint inhibitor-based strategies for the management of patients with unresectable stage III NSCLC.
  • Apply interdisciplinary care strategies for the management of stage I-III NSCLC that include methods to monitor for, identify and mitigate the impact of irAEs.

Target Audience:
These activities are intended for oncologists and other oncology health care professionals interested in the latest advances in the diagnosis, treatment and management of lung cancer.

Accreditation/Credit Designation Statement
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an independent educational grant from MJH Life Sciences.

CO-SPONSORS

TERMS OF USE & PRIVACY POLICY

 

Connect With Us: